|
DE69833940T2
(de)
|
1997-07-22 |
2006-12-14 |
Shionogi & Co., Ltd. |
Therapeutisches oder vorbeugendes mittel für glomerulopathie
|
|
BR9810841A
(pt)
*
|
1997-07-31 |
2001-07-10 |
Procter & Gamble |
Inibidores de metaloprotease alicìclicos
|
|
IL127496A0
(en)
*
|
1997-12-19 |
1999-10-28 |
Pfizer Prod Inc |
The use of MMP inhibitors for the treatment of ocular angiogenesis
|
|
US6410580B1
(en)
|
1998-02-04 |
2002-06-25 |
Novartis Ag |
Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
|
|
SK11692000A3
(sk)
|
1998-02-04 |
2001-02-12 |
Novartis Ag |
Sulfonylaminoderiváty, ktoré inhibujú metaloproteinázy degradujúce matricu, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje
|
|
US6075136A
(en)
*
|
1998-02-17 |
2000-06-13 |
Incyte Pharmaceuticals, Inc. |
Prostate-associated serine protease
|
|
US6492394B1
(en)
|
1998-12-22 |
2002-12-10 |
Syntex (U.S.A.) Llc |
Sulfonamide hydroxamates
|
|
US6313123B1
(en)
|
1999-01-27 |
2001-11-06 |
American Cyanamid Company |
Acetylenic sulfonamide thiol tace inhibitors
|
|
US6277885B1
(en)
|
1999-01-27 |
2001-08-21 |
American Cyanamid Company |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6326516B1
(en)
|
1999-01-27 |
2001-12-04 |
American Cyanamid Company |
Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6200996B1
(en)
|
1999-01-27 |
2001-03-13 |
American Cyanamid Company |
Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
|
|
US6225311B1
(en)
|
1999-01-27 |
2001-05-01 |
American Cyanamid Company |
Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
|
|
US6340691B1
(en)
|
1999-01-27 |
2002-01-22 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
|
|
US6358980B1
(en)
|
1999-01-27 |
2002-03-19 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
|
US6753337B2
(en)
|
1999-01-27 |
2004-06-22 |
Wyeth Holdings Corporation |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
|
US6946473B2
(en)
|
1999-01-27 |
2005-09-20 |
Wyeth Holdings Corporation |
Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
|
|
US6762178B2
(en)
|
1999-01-27 |
2004-07-13 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
JP2002538146A
(ja)
|
1999-03-03 |
2002-11-12 |
ザ プロクター アンド ギャンブル カンパニー |
ジヘテロ−置換メタロプロテアーゼ阻害剤
|
|
US6197770B1
(en)
|
1999-03-03 |
2001-03-06 |
The Procter & Gamble Co. |
Alkenyl- and alkynl-containing metalloprotease inhibitors
|
|
US6696456B1
(en)
*
|
1999-10-14 |
2004-02-24 |
The Procter & Gamble Company |
Beta disubstituted metalloprotease inhibitors
|
|
JP2005507937A
(ja)
|
2001-11-01 |
2005-03-24 |
ワイス・ホールディングズ・コーポレイション |
マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸
|
|
PE20030701A1
(es)
|
2001-12-20 |
2003-08-21 |
Schering Corp |
Compuestos para el tratamiento de trastornos inflamatorios
|
|
AU2002361096A1
(en)
|
2001-12-27 |
2003-07-15 |
Sumitomo Pharmaceuticals Company, Limited |
Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
|
|
JP4718172B2
(ja)
*
|
2002-06-12 |
2011-07-06 |
シンフォニー エボルーション， インク． |
ヒトａｄａｍ−１０インヒビター
|
|
AU2003304456A1
(en)
|
2002-12-23 |
2005-03-16 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
|
|
EP2106445A2
(en)
*
|
2006-12-01 |
2009-10-07 |
Loma Linda University Medical Center |
Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration
|
|
US20210393632A1
(en)
|
2018-10-04 |
2021-12-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Egfr inhibitors for treating keratodermas
|